Virus purification highlights the high susceptibility of SARS-CoV-2 to a chlorine-based disinfectant, chlorous acid.

Publication date: Jul 14, 2023

Chlorous acid water (HClO2) is known for its antimicrobial activity. In this study, we attempted to accurately assess the ability of chlorous acid water to inactivate SARS-CoV-2. When using cell culture supernatants of infected cells as the test virus, the 99% inactivation concentration (IC99) for the SARS-CoV-2 D614G variant, as well as the Delta and Omicron variants, was approximately 10ppm of free chlorine concentration with a reaction time of 10 minutes. On the other hand, in experiments using a more purified virus, the IC99 of chlorous acid water was 0. 41-0. 74ppm with a reaction time of 1 minute, showing a strong inactivation capacity over 200 times. With sodium hypochlorite water, the IC99 was 0. 54ppm, confirming that these chlorine compounds have a potent inactivation effect against SARS-CoV-2. However, it became clear that when using cell culture supernatants of infected cells as the test virus, the effect is masked by impurities such as amino acids contained therein. Also, when proteins (0. 5% polypeptone, or 0. 3% BSA + 0. 3% sheep red blood cells, or 5% FBS) were added to the purified virus, the IC99 values became high, ranging from 5. 3 to 76ppm with a reaction time of 10 minutes, significantly reducing the effect. However, considering that the usual usage concentration is 200ppm, it was shown that chlorous acid water can still exert sufficient disinfection effects even in the presence of proteins. Further research is needed to confirm the practical applications and effects of chlorous acid water, but it has the potential to be an important tool for preventing the spread of SARS-CoV-2.

Open Access PDF

Concepts Keywords
200ppm Acid
Chlorine Chlorine
Sheep Chlorous
Virus Concentration


Type Source Name
disease IDO susceptibility
drug DRUGBANK Chlorine
drug DRUGBANK Water
disease IDO cell
disease VO inactivation
disease VO time
drug DRUGBANK Amino acids
disease IDO blood
disease MESH Infectious Diseases
disease MESH infection
disease MESH COVID 19
disease MESH pneumonia
disease MESH death
pathway REACTOME Reproduction
disease VO viable
disease VO efficient
drug DRUGBANK Chlorine Dioxide
disease VO Bacteria
disease VO Fungi
disease VO effective
disease VO Viruses
disease MESH influenza
disease VO Feline calicivirus
drug DRUGBANK Human Serum Albumin
disease VO USA
drug DRUGBANK Polyethylene glycol
disease VO titer
disease VO dose
disease IDO facility
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Aspartame
disease VO volume
drug DRUGBANK Tromethamine
drug DRUGBANK Glycerin
drug DRUGBANK Activated charcoal
drug DRUGBANK Ammonium molybdate
disease IDO process
drug DRUGBANK Medical air
disease IDO infectivity
drug DRUGBANK Chloride ion
disease IDO assay
disease VO efficiency
drug DRUGBANK Coenzyme M
disease MESH viral infection
drug DRUGBANK Albendazole
disease VO effectiveness
drug DRUGBANK Hypochlorite
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK L-Cysteine
drug DRUGBANK Histidine
drug DRUGBANK Etoperidone
disease VO organization
disease MESH emergencies
drug DRUGBANK L-Tryptophan
drug DRUGBANK L-Tyrosine
drug DRUGBANK Hypochlorous acid
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Ethanol

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *